BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase Inhibitors

BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase Inhibitors

ObjectivesLittle is known regarding the outcomes of systemic treatments in BAP1-altered malignant pleural mesothelioma (MPM).Materials and MethodsForty five patients with MPM [group A: eight MPM patients with BAP1 inactivating mutation/copy number loss (FoundationOne® CDx/TEMPUSxT), selected from th...

Full description

Bibliographic Details
Main Authors: Elizabeth Dudnik, Jair Bar, Assaf Moore, Teodor Gottfried, Mor Moskovitz, Julia Dudnik, Tzippy Shochat, Aaron M. Allen, Alona Zer, Ofer Rotem, Nir Peled, Damien Urban
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Oncology
Subjects:
mesothelioma
BAP1
immune check-point inhibitors
PARP inhibitors
chemotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.603223/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.603223/full

Similar Items